Ropeginterferon alfa 2b - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
Alternative Names: A20-202; AOP-2014; BESREMi; Besremi; mono-pegylated interferon - PharmaEssentia Corporation; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b; Ropeg; Ropeginterferon alfa-2b-njft; Ropeginterferonum alfa 2b - AOP Orphan Pharmaceuticals/PharmaEssentiaLatest Information Update: 09 Sep 2024
At a glance
- Originator PharmaEssentia Corporation
- Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
- Class Antihaemorrhagics; Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Polycythaemia vera
- Phase III Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis B; Hepatitis C
- Phase II Myelofibrosis
- Phase I/II Liver cancer
- Phase I Hepatitis D
Most Recent Events
- 04 Sep 2024 Ropeginterferon alfa 2b licensed to FORUS Therapeutics in Canada
- 05 Jul 2024 Registered for Polycythaemia vera (Treatment-experienced) in China (SC)
- 25 Jun 2024 PharmaEssentia completes enrollment in phase-II EXCEED-ET trial for Essential Thrombocythemia (Treatment-experienced) in USA and Canada (SC injection) (NCT05482971)